Impact of Anti-cytomegalovirus (Valganciclovir) Treatment in the Management of Relapsing Ulcerative Colitis (UC) Requiring Vedolizumab Therapy
Condition: Ulcerative Colitis, Unspecified Intervention: Drug: Valganciclovir Sponsors: Centre Hospitalier Universitaire de Saint Etienne; Ministry of Health, France Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cytomegalovirus | France Health | Inflammatory Bowel Disease | Research | Ulcerative Colitis